On Friday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened higher 4.67% from the last session, before settling in for the closing price of $3.00. Price fluctuations for ZNTL have ranged from $2.83 to $18.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.00%. Company’s average yearly earnings per share was noted 32.96% at the time writing. With a float of $61.39 million, this company’s outstanding shares have now reached $70.77 million.
Considering the fact that the conglomerate employs 168 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 96.87%, operating margin of -516.95%, and the pretax margin is -455.68%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 13.67%, while institutional ownership is 97.54%. The most recent insider transaction that took place on Oct 04 ’24, was worth 5,098. In this transaction Principal Accounting Officer of this company sold 1,603 shares at a rate of $3.18, taking the stock ownership to the 33,855 shares. Before that another transaction happened on May 31 ’24, when Company’s President, Interim CFO sold 9,597 for $11.98, making the entire transaction worth $114,972. This insider now owns 633,680 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.79 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.91) by 0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.97 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.96% per share during the next fiscal year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 6.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.75, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -3.57 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Compared to the last year’s volume of 1.31 million, its volume of 1.3 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 46.96%. Additionally, its Average True Range was 0.24.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 3.05%, which indicates a significant decrease from 32.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.94% in the past 14 days, which was lower than the 144.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.32, while its 200-day Moving Average is $8.94. Nevertheless, the first resistance level for the watch stands at $3.21 in the near term. At $3.27, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.40. If the price goes on to break the first support level at $3.02, it is likely to go to the next support level at $2.89. Should the price break the second support level, the third support level stands at $2.83.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,026K shares outstanding in the company with a market cap of 223.29 million. Presently, the company’s annual sales total 0 K according to its annual income of -292,190 K. Last quarter, the company’s sales amounted to 40,560 K and its income totaled 10,070 K.
